Updates in NMOSD and MOGAD Diagnosis and Treatment

Cacciaguerra, Laura; Flanagan, Eoin P.

doi:10.1016/j.ncl.2023.06.009

Cited by 16 publications

(1 citation statement)

References 157 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diagnosing MOGAD has traditionally relied on clinical judgment, supported by serology testing for MOG antibodies. Given its nature as a demyelinating disorder, there is a significant overlap with NMOSD and MS in both clinical presentation and neuroradiology findings [19,20]. This underscores the need for precise diagnostic criteria for MOGAD to distinguish it from similar conditions.…”

Section: Introductionmentioning

confidence: 99%

Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings

Rechtman,

Freidman-Korn,

Zveik

et al. 2024

J Neurol

View full text Add to dashboard Cite

Introduction Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified demyelinating disorder with a diverse clinical spectrum. Diagnosing MOGAD traditionally relies on clinical judgment, highlighting the necessity for precise diagnostic criteria. Banwell et al. proposed criteria, aiming to refine the diagnostic spectrum. This study evaluates these criteria in a real-life cohort, comparing their performance with clinical judgment and describe the cohort of MOGAD patients. Methods This retrospective study, conducted at Hadassah Medical Center, included 88 patients with MOG-IgG antibodies. Patients with a positive or borderline MOG-IgG antibodies by cell-based assay were included. Demographics, clinical and MRI data were recorded. Cases were divided into definite MOGAD and Non-MOGAD groups as determined by the treating physician. We assessed the sensitivity and specificity of the new criteria in comparison to treating physicians’ evaluations. Additionally, we examined clinical differences between the MOGAD and Non-MOGAD groups. Results We observed a strong concordance (98%) between the new MOGAD criteria and treating physicians' diagnoses. Clinical disparities between MOGAD and Non-MOGAD groups included lower EDSS scores, normal MRI scans, preserved brain volume, negative OCB results, and distinct relapse patterns. Also, compared to relapsing patients, monophasic MOGAD patients have greater brain volume and a lower age at onset. Conclusion The study demonstrates robust accuracy of new MOGAD criteria, emphasizing their potential to enhance diagnostic precision. Treatment response integration into the MOGAD diagnosis is crucial, as it could aid in distinguishing MOGAD from other demyelinating disorders. Distinct clinical profiles highlight the importance of informed decisions in managing MOGAD and similar disorders.

show abstract

Section: Introductionmentioning

confidence: 99%

Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings

Rechtman,

Freidman-Korn,

Zveik

et al. 2024

J Neurol

View full text Add to dashboard Cite

show abstract

Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations

Hua,

Solomon,

Tenembaum

et al. 2024

JAMA Neurol

View full text Add to dashboard Cite

ImportanceWhile the typical onset of multiple sclerosis (MS) occurs in early adulthood, 2% to 10% of cases initially present prior to age 18 years, and approximately 5% after age 50 years. Guidance on approaches to differential diagnosis in suspected MS specific to these 2 age groups is needed.ObservationsThere are unique biological factors in children younger than 18 years and in adults older than age 50 years compared to typical adult-onset MS. These biological differences, particularly immunological and hormonal, may influence the clinical presentation of MS, resilience to neuronal injury, and differential diagnosis. While mimics of MS at the typical age at onset have been described, a comprehensive approach focused on the younger and older ends of the age spectrum has not been previously published.Conclusions and RelevanceAn international committee of MS experts in pediatric and adult MS was formed to provide consensus guidance on diagnostic approaches and key clinical and paraclinical red flags for non-MS diagnosis in children and older adults.

show abstract

Dural arteriovenous fistula masquerading as neuromyelitis optica spectrum disorder

Bourdoncle,

Papeix,

Lecler

2024

Diagnostic and Interventional Imaging

View full text Add to dashboard Cite

Updates in NMOSD and MOGAD Diagnosis and Treatment

Cited by 16 publications

References 157 publications

Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings

Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings

Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations

Dural arteriovenous fistula masquerading as neuromyelitis optica spectrum disorder

Contact Info

Product

Resources

About